Rotavirus Infection Clinical Trial
Official title:
Two Year (2009-2010) Surveillance of Rotavirus Genotypes Causing Acute Diarrhea in Children Younger Than 5 Years of Age Requiring Emergency Room and Hospital Admission in Two Large Cities in Chile.
The purpose of this study is to prospectively determine the rotavirus VP7/VP4 genotypes associated with moderate to severe disease (requiring emergency room (ER) consult or hospitalization) in a large public hospital from Valparaiso and another from Santiago.
Rotavirus is the leading cause of gastroenteritis in children. Our group has developed a surveillance system for acute rotavirus diarrhea in two large hospitals in Chile since 2006. Patients visiting the ER for acute non-bloody diarrhea will be enrolled after an informed consent is signed by parents. A fresh stool sample will be collected to prospectively determine the rotavirus VP7/VP4 genotypes associated with moderate to severe disease (requiring emergency room (ER) consult or hospitalization. Stool samples will be tested for rotavirus by ELISA IDEIA - Rotavirus - OXOID. Rotavirus positive samples will be genotyped as described previously (Iturriza-Gomara et al. J. Clinical Virol 2004). Overall medical visits and hospitalizations, proportion of visits and hospitalizations caused by acute diarrhea, estimated numbers of rotavirus visits and hospitalizations will be calculated for each site. Proportion of rotavirus VP7 and VP4 genotypes will be calculated for three month periods per center. Differences in proportion will be compared by chi square and Fischer's exact test when appropriate. ;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03207750 -
This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine
|
Phase 3 | |
| Completed |
NCT01266850 -
Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules
|
Phase 4 | |
| Completed |
NCT02992197 -
The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and Immunogenicity
|
Phase 4 | |
| Completed |
NCT00981877 -
Probiotics in the Management of Acute Rotavirus Diarrhea in Bolivian Children
|
N/A | |
| Completed |
NCT05032391 -
Reactogenicity, Safety and Immunological Efficacy of the Live, Pentavalent Rotavirus Vaccine in Childhood Immunization
|
Phase 3 | |
| Active, not recruiting |
NCT02662543 -
The Epidemiology and Etiology of Acute Gastroenteritis Among Estonian Children After Introduction of Rotavirus Vaccines
|
N/A | |
| Completed |
NCT00302640 -
Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in Children
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT04626856 -
Safety and Preliminary Immunogenicity Study of Inactivated Vaccine for Prevention of Rotavirus Infection
|
Phase 1 | |
| Completed |
NCT01764256 -
A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine
|
Phase 1 | |
| Completed |
NCT00880698 -
Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers
|
Phase 2 | |
| Completed |
NCT01328925 -
Efficacy Study of Nitazoxanide Suspension in the Treatment of Rotavirus Disease in Children
|
Phase 2 | |
| Completed |
NCT00683982 -
Use of Nitazoxanide and Probiotics in Acute Diarrhea Secondary to Rotavirus
|
N/A | |
| Completed |
NCT01511133 -
Serological Response to Porcine Circovirus Type 1 (PCV-1) and PCV-1 DNA in Stools of Infants Following Administration of Rotarix™
|
N/A |